ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Melanoma

Immunotherapy Combination Active in Advanced Melanoma

Treatment with nivolumab and ipilimumab in patients with advanced melanoma produced significantly higher rates of response and progression-free survival compared with ipilimumab alone.

Melanoma

By exploring gene expression variables in addition to clinicopathologic variables, researchers were able to better predict which melanoma patients would have sentinel lymph node biopsy positivity.

The unprecedented advances in melanoma immunotherapy are sure to pave the way for immunotherapy development in other tumors.

Frequent consumers of citrus fruits were found to have an elevated risk of malignant melanoma.

New data suggests that cutaneous melanomas can be classified into four subtypes based on the pattern of the most prevalent significantly mutated genes.

A study of men taking PDE5 inhibitors found a small but significant increase in the incidence of malignant melanoma, though the association may not be causal.

As part of our 2015 ASCO Annual Meeting coverage, we discussed immunotherapy combinations in advanced melanoma patients with Michael A. Postow, MD.

Updated results from the coBRIM trial show that a BRAF/MEK inhibitor combination continues to provide clinical benefit in BRAF-positive metastatic melanoma.

Pages

Subscribe to Melanoma on [sitename]
  • When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, D, and E of skin cancer—asymmetry, border, color, diameter, and evolving.

By clicking Accept, you agree to become a member of the UBM Medica Community.